Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study

International Journal of Obesity volume 34, pages 1255–1264 (2010)Cite this article

Subjects

Abstract

Objective:

We aimed at evaluating whether the addition of low-dose metformin to dietary treatment could be an effective approach in nondiabetic patients with nonalcoholic fatty liver disease (NAFLD).

Methods:

We carried out a 6-month prospective study in a series of overweight or obese patients with ultrasonographic diagnosis of hepatic steatosis. In total, 50 patients were enrolled and randomized into two groups: the first group (n=25) was given metformin (1 g per day) plus dietary treatment and the second group (n=25) was given dietary treatment alone.

Results:

At the end of the study, the proportion of patients with echographic evidence of fatty liver was reduced in both the metformin (P<0.0001) and the diet group (P=0.029). Moreover, patient body mass index and waist circumference significantly decreased in both groups (P<0.001). Fasting glucose, insulin resistance (evaluated as homeostasis model assessment of insulin resistance (HOMA-IR)) and serum adiponectin decreased in both groups, although these changes reached statistical significance only in the metformin group. In this group, HOMA-IR decreased from 3.3±1.6 to 2.4±1.2 (P=0.003), whereas it decreased from 3.2±1.6 to 2.8±1.1 (not significant, NS) in the diet group. Similarly, the proportion of patients with impaired fasting glucose declined from 35 to 5% (P=0.04) in the metformin and from 32 to 12% (NS) in the diet group. At baseline, ∼40% of patients in both groups met the diagnostic criteria of metabolic syndrome. This proportion decreased to 20% in the metformin group (P=0.008) and to 32% in the diet group (NS).

Conclusions:

In our 6-month prospective study, both low-dose metformin and dietary treatment alone ameliorated liver steatosis and metabolic derangements in patients with NAFLD. However, metformin was more effective than dietary treatment alone in normalizing several metabolic parameters in these patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Bellentani S, Marino M . Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2009; 8 (Suppl 1): S4–S8.

    PubMed  Google Scholar 

  2. Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G . Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004; 5: 27–42.

    Article  CAS  Google Scholar 

  3. Bugianesi E, Zannoni C, Vanni E, Marzocchi R, Marchesini G . Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? Dig Liver Dis 2004; 36: 165–173.

    Article  CAS  Google Scholar 

  4. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844–1850.

    Article  CAS  Google Scholar 

  5. Vuppalanchi R, Chalasani N . Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 2009; 49: 306–317.

    Article  Google Scholar 

  6. Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ . Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009; 2009: 831670.

    Article  Google Scholar 

  7. Socha P, Horvath A, Vajro P, Dziechciarz P, Dhawan A, Szajewska H . Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009; 48: 587–596.

    Article  CAS  Google Scholar 

  8. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004; 2: 1107–1115.

    Article  CAS  Google Scholar 

  9. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1176–1184.

    Article  CAS  Google Scholar 

  10. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39: 188–196.

    Article  CAS  Google Scholar 

  11. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355: 2297–2307.

    Article  CAS  Google Scholar 

  12. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008; 135: 100–110.

    Article  CAS  Google Scholar 

  13. Wang CC, Huang HT . Voice aerodynamic analysis of normal Taiwanese adults. J Formos Med Assoc 2005; 104: 868–872.

    PubMed  Google Scholar 

  14. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR . Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008–1017.

    Article  CAS  Google Scholar 

  15. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N . Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893–894.

    Article  CAS  Google Scholar 

  16. Nair S, Diehl AM, Wiseman M, Farr Jr GH, Perrillo RP . Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23–28.

    Article  CAS  Google Scholar 

  17. Uygun A, Kadayifci A, Isik AT, Ozgurtas T, Deveci S, Tuzun A et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19: 537–544.

    Article  CAS  Google Scholar 

  18. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005; 100: 1082–1090.

    Article  CAS  Google Scholar 

  19. Nobili V, Manco M, Ciampalini P, Alisi A, Devito R, Bugianesi E et al. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther 2008; 30: 1168–1176.

    Article  CAS  Google Scholar 

  20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419.

    Article  CAS  Google Scholar 

  21. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R . Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003; 26: 3320–3325.

    Article  CAS  Google Scholar 

  22. Palmentieri B, de Sio I, La Mura V, Masarone M, Vecchione R, Bruno S et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis 2006; 38: 485–489.

    Article  CAS  Google Scholar 

  23. Roldan-Valadez E, Favila R, Martinez-Lopez M, Uribe M, Mendez-Sanchez N . Imaging techniques for assessing hepatic fat content in nonalcoholic fatty liver disease. Ann Hepatol 2008; 7: 212–220.

    PubMed  Google Scholar 

  24. National Institutes Of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report National Institutes Of Health. Obes Res 1998; 6 (Suppl 2): 51S–209S.

    Google Scholar 

  25. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735–2752.

    Article  Google Scholar 

  26. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.

    Article  CAS  Google Scholar 

  27. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth joint task force of the European Society Of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 (Suppl 2): E1–E40.

    Article  Google Scholar 

  28. Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.

    Article  Google Scholar 

  29. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917–923.

    Article  Google Scholar 

  30. Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H . Liver fat in the metabolic syndrome. J Clin Endocrinol Metab 2007; 92: 3490–3497.

    Article  CAS  Google Scholar 

  31. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005; 100: 1072–1081.

    Article  Google Scholar 

  32. Park HS, Kim MW, Shin ES . Effect of weight control on hepatic abnormalities in obese patients with fatty liver. J Korean Med Sci 1995; 10: 414–421.

    Article  CAS  Google Scholar 

  33. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004; 53: 413–419.

    Article  CAS  Google Scholar 

  34. Suzuki A, Lindor K, St Saver J, Lymp J, Mendes F, Muto A et al. Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease. J Hepatol 2005; 43: 1060–1066.

    Article  CAS  Google Scholar 

  35. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI . Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005; 54: 603–608.

    Article  CAS  Google Scholar 

  36. Kirpichnikov D, McFarlane SI, Sowers JR . Metformin: an update. Ann Intern Med 2002; 137: 25–33.

    Article  CAS  Google Scholar 

  37. Loomba R, Lutchman G, Kleiner DE, Ricks M, Feld JJ, Borg BB et al. Clinical trial: pilot study of metformin for the treatment of nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2008; 29: 172–182.

    Article  Google Scholar 

  38. He L, Sabet A, Djedjos S, Miller R, Sun X, Hussain MA et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 2009; 137: 635–646.

    Article  CAS  Google Scholar 

  39. Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T et al. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med 2008; 21: 507–511.

    CAS  PubMed  Google Scholar 

  40. Musso G, Gambino R, Bo S, Uberti B, Biroli G, Pagano G et al. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care 2008; 31: 562–568.

    Article  CAS  Google Scholar 

  41. Haukeland JW, Konopski Z, Eggesbo HB, von Volkmann HL, Raschpichler G, Bjoro K et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scand J Gastroenterol 2009; 44: 853–860.

    Article  CAS  Google Scholar 

  42. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286–1292.

    Article  Google Scholar 

  43. Tobari M, Hashimoto E, Yatsuji S, Torii N, Shiratori K . Imaging of nonalcoholic steatohepatitis: advantages and pitfalls of ultrasonography and computed tomography. Intern Med 2009; 48: 739–746.

    Article  Google Scholar 

  44. Lilly M, Godwin M . Treating prediabetes with metformin: systematic review and meta-analysis. Can Fam Physician 2009; 55: 363–369.

    PubMed  PubMed Central  Google Scholar 

  45. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288–1295.

    Article  CAS  Google Scholar 

  46. Wieckowska A, McCullough AJ, Feldstein AE . Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46: 582–589.

    Article  CAS  Google Scholar 

  47. Angulo P . Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221–1231.

    Article  CAS  Google Scholar 

  48. Gaidos JK, Hillner BE, Sanyal AJ . A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis. Liver Int 2008; 28: 650–658.

    Article  Google Scholar 

  49. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722–728.

    Article  CAS  Google Scholar 

  50. Castera L . Non-invasive diagnosis of steatosis and fibrosis. Diabetes Metab 2008; 34: 674–679.

    Article  CAS  Google Scholar 

  51. Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ . Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 2009; 51: 1061–1067.

    Article  Google Scholar 

  52. Duseja A, Das A, Dhiman RK, Chawla YK, Thumburu KT, Bhadada S et al. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann Hepatol 2007; 6: 222–226.

    CAS  PubMed  Google Scholar 

  53. de Oliveira CP, Stefano JT, de Siqueira ER, Silva LS, de Campos Mazo DF, Lima VM et al. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol Res 2008; 38: 159–165.

    CAS  PubMed  Google Scholar 

  54. Idilman R, Mizrak D, Corapcioglu D, Bektas M, Doganay B, Sayki M et al. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008; 28: 200–208.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical and Experimental Medicine, Endocrinology Unit, University Magna Graecia of Catanzaro, Catanzaro, Italy

    G A Garinis, B Fruci, A Mazza & A Belfiore

  2. Hepatology Unit, Azienda Ospedaliera Mater Domini, Catanzaro, Italy

    M De Siena & S Abenavoli

  3. Department of Clinical and Experimental Medicine, Clinical Pathology Unit, University Magna Graecia of Catanzaro, Catanzaro, Italy

    E Gulletta, V Ventura & M Greco

  4. Department of Clinical and Experimental Medicine, Digestive Physiopathology Unit, University Magna Graecia of Catanzaro, Catanzaro, Italy

    L Abenavoli

Authors
  1. G A Garinis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Fruci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Mazza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M De Siena
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Abenavoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E Gulletta
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. V Ventura
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Greco
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L Abenavoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A Belfiore
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Belfiore.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Garinis, G., Fruci, B., Mazza, A. et al. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes 34, 1255–1264 (2010). https://doi.org/10.1038/ijo.2010.40

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ijo.2010.40

Keywords

This article is cited by

Search

Advanced search

Quick links